Please login to the form below

Not currently logged in
Email:
Password:

Axovant poaches Allergan’s and Teva’s chief medical and science officers

Gavin Corcoran and Michael Hayden join the biopharma

Gavin and MichaelClinical stage biopharmaceutical group Axovant has appointed Gavin Corcoran as its new executive vice president of research and development.

Corcoran’s career history has seen him supervise drug development across multiple therapeutic areas including neurology and psychiatry.

Most recently, Corcoran served as chief medical officer at Allergan and before that he was Actavis’ chief medical officer.

Throughout his career he has served in numerous roles for Celgene, Amgen, Schering-Plough and Bayer.

Corcoran said: “I look forward to working closely with the senior management team to bring new investigational medicines into the portfolio as we build upon Axovant’s capabilities in research and development.

“We have a wonderful opportunity to develop life-changing medicines for patients with CNS diseases.

“I am also eager to leverage the Roivant platform to accelerate the development of Axovant’s pipeline.”

Meanwhile, Teva’s former chief scientific officer Michael Hayden will also join Axovant, serving as its chairman of the scientific advisory board.

Prior to his time at Teva as its president of global research and development and chief scientific officer, Hayden founded multiple biotechnology companies including Aspreva Pharmaceuticals.

Pavan Cheruvu, chief executive officer, Axovant, said: “Since starting as CEO in February, I have been focused on transforming Axovant into a leaner organisation, introducing heightened standards of quality and excellence throughout the business, and establishing a new pipeline strategy.

“We are now poised for growth, and I am excited to have Gavin and Michael join us as we look toward expanding our pipeline in the coming months.”

5th June 2018

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Accession

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...
Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...